Skip to main content

Advertisement

SpringerLink
Log in

Phase IV group study of natural human interferon alpha (HLBI) on chronic myelogeneous leukaemia

  • Research Articles
  • Published:
Biotherapy

Abstract

Under the control of Kanagawa CML/HLBI phase IV study group in Japan, 18 cases out of registered 30 cases of chronic myelogeneous leukaemia consisting of 17 chronic phase and 1 accelerated phase, during July, 1991 to January, 1992, were analyzed for their hematological responses and cytogentic responses preliminarily. Hematological response rate (PR + CR) was 83.3% including 50.0% of CR, as judged by Kimura's criteria after treatment with HLBI alone (16 cases) or/and with other chemotherapy (2 cases). The dosage and duration of HLBI therapy required to get into the complete remission ranged from 212 to 1272 millions IU and between 6 to 42 weeks (mean value was 20 weeks), respectively. The clonally proliferated leukocytes and decreased physiological hematopoiesis started to recover from 2 to 4 weeks and reached their normal ranges from 16 weeks after 6 millions IU of HLBI were administered every day. In the 4 cases examined, 3 cases showed minimal cytogenetic responses and a case showed no cytogenetic response. Slight and temporary adverse effects were observed in 15 out of 18 cases (83.3%) including fever, general malaise, appetite loss, eruption, diarrhea, glossitis, hypogustation, weight loss and local muscle pain.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

HLBI:

Human interferon alpha originated from human lymphoblastoid cell line

References

  1. Koeffler HP, Golde DW. Chronic myelogeneous leukaemia: new concepts. N. Engl J Med 1981; 304: 1269–74.

    PubMed  Google Scholar 

  2. Tura S, Baccarani M, Corbelli G. The Italian cooperative study group on chronic myeloid leukemia. Staging of chronic myeloid leukaemia. Brit J Haemat 1981; 47: 105–119.

    PubMed  Google Scholar 

  3. Minot GR, Buckman TE, Isaacs R. Chronic myelogenous leukaemia: age, incidence, duration and benefit derived from irradiation, J A M A 1924; 82: 1489–1494.

    Google Scholar 

  4. Jacobs P, Dubovsky D, King H, Sealey R. Splenic irradiation in the management of chronic granulocytic leukaemia. Cent Afri J Med 1975; 21: 207–210.

    Google Scholar 

  5. Medical Research Council's Working Party for Therapeutic Trials in Leukaemia. Chronic granulocyte leukaemia: comparison of radiotherapy and busulfan therapy. Brit Med J 1968; 1: 201–208.

    Google Scholar 

  6. Reinhard EH, Neely L, Samples DM. Radioactive phosphorus in the treatment of chronic leukaemias: long-term results over a period of 15 years. Ann Int Med 1959; 50: 942–958.

    PubMed  Google Scholar 

  7. Haut A, Abbott WS, Wintrobe MM, Cartwright GE. Busulfan in the treatment of chronic myelocytic leukaemia. The effect of long term intermittent therapy. Blood 1961; 17: 1–19.

    PubMed  Google Scholar 

  8. Silver RT, Mick R, Cooper R, Ellison RR, Levy R, Brunner K, Schwartz JM, Holland JF. Comparative study of dibromomannitol and busulfan in the treatment of chronic myeloid leukaemia. A study of cancer and leukaemia group. Cancer 1987; 60: 1442–1448.

    PubMed  Google Scholar 

  9. Schwarzenberg L, Mathe G, Pouillart P, Weiner R, Locour J, Genin JL, Schneider M, deVasal F, Hayat M, Amiel JL, Schlumberger JR, Jasmin C, Rosenfeld C. Hydroxyurea, leukapheresis, and splenectomy in chronic myeloid leukaemia at the pro-blastic phase. Brit Med J. 1973; 1: 700–703.

    PubMed  Google Scholar 

  10. Tura S, Baccarini M, Gugliotta L, Lauria F, Fiacchini M, Tomasini I. A clinical trial of early splenectomy, hydroxyurea, and cyclic arabinosylcytosine, vincristine, and prednisone in chronic myeloid leukaemia. Ser Haematol. 1975; 8: 121–142.

    PubMed  Google Scholar 

  11. Kantarjian HM, Vellekoop L, McCredie KB, Keating MJ, Hestner J, Smith T, Barlogie,. Trujullo J, Freireich EJ. Intensive combination chemotherapy (ROAP 10) and splenectomy in the management of chronic myelogenous leukaemia. J Clin Oncol 1985; 3: 192–200.

    PubMed  Google Scholar 

  12. Medical Research Council's Working Party for Therapeutic Trials in Leukaemia. Randomized trial of splenectomy in Ph1-positive chronic granulocytic leukaemia, including an analysis of prognostic features. Brit J Haemat 1983; 54: 415–430.

    Google Scholar 

  13. Goldman JM, Apperley JF, Jones L, Marcus R, Goolden AWG, Batchelor R, Hale G, Waldmann H, Reid CD, Hows J, Gordon-Smith E, Catovsky D, Galton AG. Bone marrow transplantation for patients with chronic myeloid leukaemia. N Engl J Med 1986; 314: 202–207.

    PubMed  Google Scholar 

  14. Singer JW, Arlin ZA, Najfeld V, Adamson JW, Kempin SJ, Clarkson BD, Fialkow PJ. Restoration of nonclonal hematopoiesis in chronic myelogenous leukaemia (CML) following a chemotherapy-induced loss of the Ph1 chromosome. Blood 1980; 56: 356–360.

    PubMed  Google Scholar 

  15. Talpaz M, Kantarjian HM, McKredie K, Trujillo JM, Keating MJ, Gutterman J. Hematologic remission and cytogenetic improvement induced by recombinant interferon alpha in chronic myelogenous leukaemia. N Engl J Med 1986; 314: 1065–1069.

    PubMed  Google Scholar 

  16. Kimura I, Kitajima K. Chronic leukaemia. In: Saito T. eds. Pharmacological Treatment of Cancer: Development and Judgement of Effects. Tokyo: Realize Inc. 1985: 359–366.

    Google Scholar 

  17. Koyama S, Moriyama Y, Shibata A, Miura Y, Abe T, Asano S, Miyazaki T, Miura A, Kariyone S, Toyama K, Hirano M, Furuta S, Ohta T, Takino T, Maekawa T, Hayashi H, Haruyama H, Hosoda S, Masaoka T, Kuramoto A, Kamata N, Oguma N, Ishimaru M. Clinical investigation of natural interferon alpha (HLBI) in chronic myelogenous leukaemia. A multi-institutional cooperative study in Japan. Jpn J Cancer Chemother 1988; 15: 2959–2968.

    Google Scholar 

  18. Hozler JC, Lindquist LL. Banded karyotypes from bone marrow. A clinically useful approach. Human Genet 1980; 53: 205–209.

    Google Scholar 

  19. McGrlave PB, Miller WJ, Hurd DD, Arthur DC, Kim T. Cytogenetic conversion following allogeneic bone marrow transplantation for advanced chronic myelogenous leukaemia. Blood 1981; 58: 1050–1052.

    PubMed  Google Scholar 

  20. Lee M-S, LeMaistre A, Kantarjian HM, Talpaz M, Freireich EJ, Trujillo JM, Stass SA. Detection of two alternative bcr/abl mRNA junction and minimal residual disease in Philadelphia chromosome positive chronic myelogenous leukaemia by polymerase chain reaction. Blood 1989; 73: 2165–2170.

    PubMed  Google Scholar 

  21. WHO:WHO handbook for reporting results of cancer treatment. Geneva: WHO, 1979.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Medicine and Hematology, Tokai University School of Medicine, Japan

    Shigeru Arimori

  2. Departments of Medicine and Hematology, International St. Luka Hospital, Japan

    Hideo Terada

  3. Departments of Medicine and Hematology, Yokohama National Hospital, Japan

    Kazuo Hayami

  4. Departments of Medicine and Hematology, Yokosuka Mutual Aid Hospital, Japan

    Yoshitaka Aoyagi

  5. Departments of Medicine and Hematology, Yokohama City University School of Medicine, Japan

    Shigeki Motomura & Hitoshi Fukawa

  6. Departments of Medicine and Hematology, Yokohama Municipal Citizen's Hospital, Japan

    Noriko Akatsuka

  7. Departments of Medicine and Hematology, St. Marianna University School of Medicine, Japan

    Susumu Shimizu

  8. Departments of Medicine and Hematology, Kanagawa Cancer Center, Japan

    Fumio Kodama

  9. Departments of Medicine and Hematology, Yokohama Hospital for Labor Welfare Corporation, Japan

    Shozou Chiba

  10. Departments of Medicine and Hematology, Teikyo University School of Medicine, Japan

    Akio Urabe

  11. Departments of Medicine and Hematology, Showa University Fujigaoka Hospital, Japan

    Mitsuhiro Omine

  12. Departments of Medicine and Hematology, Kawasaki Municipal Hospital, Japan

    Keiichi Harada

Authors
  1. Shigeru Arimori
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hideo Terada
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kazuo Hayami
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yoshitaka Aoyagi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Shigeki Motomura
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hitoshi Fukawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Noriko Akatsuka
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Susumu Shimizu
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Fumio Kodama
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Shozou Chiba
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Akio Urabe
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Mitsuhiro Omine
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Keiichi Harada
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Arimori, S., Terada, H., Hayami, K. et al. Phase IV group study of natural human interferon alpha (HLBI) on chronic myelogeneous leukaemia. Biotherapy 6, 149–153 (1993). https://doi.org/10.1007/BF01877428

Download citation

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01877428

Key words

Search

Navigation